Condition: Persistent Spinal Pain Syndrome Type 2 · Spinal Cord Stimulation · Sponsor: Moens Maarten
The primary objective of the study is to examine whether there is a difference in disability after 12 months of Spinal Cord Stimulation (SCS) in patients with Persistent Spinal Pain Syndrome Type 2 (PSPS T2) after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation. The secondary objective of the study is to examine whether there is a difference after 12 months of SCS in PSPS T2 patients after receiving a standardized pain medication tapering protocol before SCS implantation, a personalized pain medication tapering protocol before SCS implantation, or no tapering protocol before SCS implantation on pain intensity, health-related quality of life, participation, domains affected by substance use, anxiety and depression, medication use, psychological constructs, sleep, central sensitization, and healthcare expenditure.
This description comes directly from the study's public registry record.
Maarten Moens, Prof, Dr. · +3224775514 · stimulusresearchgroup@gmail.com
Lisa Goudman, Prof, Dr. · +3224775514 · stimulusresearchgroup@gmail.com
Always discuss trial participation with your own doctor first.
| Universitair Ziekenhuis Brussel | Jette, Belgium | Recruiting |
| Heilig Hart Ziekenhuis Lier | Lier, Belgium | Not Yet Recruiting |
| AZ Delta | Roeselare, Belgium | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05861609